RxDoctor Payments Data

Iqbal Saeed, MD

Internal Medicine · Huntsville, ALNPI 1235170622

Payments from drug & device makers

$5,057in general payments, 2019–2025

Across 320 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$368
  • GSK$350
  • Amgen$208
  • Kowa Pharmaceuticals America, Inc.$202
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$5,03199%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,057 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$178,056
Medicare patients
331
Services billed
2,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide109$153,866
OzempicSemaglutide86$123,371
EliquisApixaban53$68,070
JanuviaSitagliptin Phosphate56$65,181
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$50,477
JardianceEmpagliflozin29$44,165
RybelsusSemaglutide17$40,216
FarxigaDapagliflozin Propanediol28$25,441
EntrestoSacubitril/Valsartan19$23,412
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$17,414
Tresiba Flextouch U-200Insulin Degludec11$12,292
Atorvastatin Calcium490$6,663
Losartan Potassium433$5,575
Humalog Kwikpen U-100Insulin Lispro11$5,331
Albuterol Sulfate HfaAlbuterol Sulfate103$5,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,417$163,587103 claims
Lilly USA, LLCMounjaro$172$153,866109 claims
PfizerEliquis, Premarin$368$72,87566 claims
MerckJanuvia$189$65,18156 claims
GSKTrelegy Ellipta$350$50,47744 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,023$47,93453 claims
Boehringer IngelheimJardiance$97$44,16529 claims
NovartisEntresto$182$23,41219 claims
AbbVieSynthroid$81$1,57218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →